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Chronic GLP-1 Receptor Activation by Exendin-4 Induces
Expansion of Pancreatic Duct Glands in Rats and
Accelerates Formation of Dysplastic Lesions and Chronic
Pancreatitis in the KrasG12D Mouse Model
Belinda Gier,1 Aleksey V. Matveyenko,1 David Kirakossian,1 David Dawson,2,3 Sarah M. Dry,2,3 and
Peter C. Butler1,3
Pancreatic duct glands (PDGs) have been hypothesized to give rise
to pancreatic intraepithelial neoplasia (PanIN). Treatment with the
glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks
induced the expansion of PDGs with mucinous metaplasia and
columnar cell atypia resembling low-grade PanIN in rats. In the
pancreata of Pdx1-Cre; LSL-KrasG12D mice, exendin-4 led to ac-
celeration of the disruption of exocrine architecture and chronic
pancreatitis with mucinous metaplasia and increased formation
of murine PanIN lesions. PDGs and PanIN lesions in rodent and
human pancreata express the GLP-1 receptor. Exendin-4 induced
proproliferative signaling pathways in human pancreatic duct cells,
cAMP–protein kinase A and mitogen-activated protein kinase phos-
phorylation of cAMP-responsive element-binding protein, and in-
creased cyclin D1 expression. These GLP-1 effects were more
pronounced in the presence of an activating mutation of Kras and
were inhibited by metformin. These data reveal that GLP-1 mimetic
therapy may induce focal proliferation in the exocrine pancreas
and, in the context of exocrine dysplasia, may accelerate formation
of neoplastic PanIN lesions and exacerbate chronic pancreatitis.
Diabetes 61:1250–1262, 2012
Glucagon-like peptide (GLP)-1 is a proglucagon-derived peptide secreted by gut endocrine cells(L cells) in response to meal ingestion (1). TheGLP-1 receptor (GLP-1R) is a G-protein–coupled
receptor that is expressed in pancreatic islets and exocrine
duct cells (2,3). The increased GLP-1 released after meal
ingestion amplifies postprandial nutrient-driven insulin
secretion, the so-called incretin effect (4). Based on this
property, GLP-1R activation became an attractive thera-
peutic target for type 2 diabetes mellitus (T2DM).
To overcome the short half-life of circulating GLP-1 that
is rapidly degraded by dipeptidyl peptidase (DPP)-4 (5), two
strategies have been used in drug development. Oral DPP-4
small molecule inhibitors, such as sitagliptin, prolong the
half-life of endogenously secreted GLP-1 (6). Alternatively,
GLP-1R peptide agonists given by injection, such as
exenatide (7) and liraglutide (8), are resistant to DPP-4
degradation.
Pancreatitis emerged as an unexpected side effect of
GLP-1–based therapy in case reports (9,10), and in the U.S.
Food and Drug Administration adverse-event reports,
liraglutide and sitagliptin showed a signal of pancreatitis
(11–13), although analysis of insurance claims records
have been reported to show no association between GLP-
1–based therapy and pancreatitis (14). Because the human
pancreas is inaccessible in treated patients, the question
as to whether GLP-1 mimetic therapy acts on the exocrine
pancreas has been a subject of animal-based studies.
Pancreatic duct cell proliferation increased transiently
with a GLP-1 infusion in Wistar rats (15). Sprague-Dawley
rats treated with exendin-4 for 12 weeks developed low-
grade chronic pancreatitis (16). Furthermore, DPP-4 in-
hibition with sitagliptin for 12 weeks was associated with
increased pancreatic duct cell replication and acinar-to-
ductal metaplasia and, in 1 of 10 rats, chronic pancreatitis
(3). However, GLP-1–based therapy also has been reported
to not exacerbate chemically induced pancreatitis in mice
(17). Also, exenatide was reported to have no effect on
ductal turnover in mice or rats, as well as to have a ben-
eficial action in chemically induced pancreatitis (18).
Pancreatic duct glands (PDGs), under conditions of
chronic injury, such as chemically induced pancreatitis,
may give rise to lesions resembling pancreatic intraepithelial
neoplasia (PanIN) (19). To date, there is no information on
the actions of GLP-1–based therapy on PDGs or the de-
velopment of PanIN in pancreata predisposed to dyspla-
sia. Here, we sought to address the following questions.
First, does chronic activation of GLP-1Rs by exendin-4 lead
to proliferation of the PDGs? Second, is GLP-1R expression
present in PDGs and PanIN-like dysplastic lesions? Third,
does chronic activation of GLP-1Rs alter the phenotype of
Pdx1-Cre; LSL-KrasG12D (Pdx1-Kras) mice?
RESEARCH DESIGN AND METHODS
Rodent studies. All animal studies were approved by the animal use and care
committee at the University of California Los Angeles (UCLA). Animals were
housed individually in a 12-h light/dark cycle and were weighed weekly to
adjust drug doses. Blood glucose and food intakeweremonitored on a biweekly
basis.
Sprague-Dawley rats treated with exendin-4. To establish the actions of
GLP-1R activation in the exocrine pancreas, we treated 10 male Sprague-
Dawley rats (Charles River Laboratories, Wilmington, MA) with daily injections
of 10 mg/kg body wt exendin-4 (ChemPep, Miami, FL) administered by sub-
cutaneous injection for 12 weeks starting at 10 weeks of age (20). Animals
were fed chow (Teklad; Harlan Laboratories, Madison, WI) ad libitum. A total
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of 15 control rats received daily saline injections. We did not identify PDGs in
5 of 15 controls; therefore, these 5 rats were not included in subsequent
analyses. PDGs were identified in all treated rats.
Pdx1-Kras mice treated with exendin-4. To investigate the effect of
chronic GLP-1 mimetic treatment on pancreatic cancer precursor lesions, the
conditional KrasG12D from Hingorani et al. (21) was used. Experimental ani-
mals were generated by crossing Pdx1-Cre with LSL-KrasG12D mice on a C57/
BL6 background (both gifts of Guido Eibl, UCLA). Mice (6 weeks old) were
fed an AIN-76A–based diet (Research Diets, New Brunswick, NJ) ad libitum
for 12 weeks, during which either saline (n = 7) or exendin-4 (5 nmol/kg body
wt) (n = 5) was injected subcutaneously daily.
Pancreas fixation, embedding, and sectioning
Rat pancreas. After the rats were killed, the rat pancreata were rapidly
dissected and then divided into two portions (the head and body of the pancreas
and the tail of the pancreas). These were fixed in 4% paraformaldehyde
overnight at 4°C and embedded in paraffin, oriented flat to permit subsequent
microscopic sections to be made through the longitudinal plane of the pancreas.
The block containing the head and body of the pancreas was sectioned at 4-mm
intervals to obtain a minimum of 40 sections through the longitudinal plane of
the pancreas. A minimum of 10 serial sections were obtained per block from the
tail of the pancreas.
Mouse pancreas. Successful excision-recombination events were confirmed
by genotyping analysis (Transnetyx, Cordova, TN). Paraformaldehyde-fixed,
paraffin-embedded pancreatic sections (4 mm) of whole pancreas were stained
as below.
Human pancreas. Paraffin-embedded tissue blocks of nonneoplastic human
pancreata adjacent to surgically resected pancreatic adenocarcinoma were
selected from 10 case subjects from the UCLA pathology archives. All slides and
tissue blocks were retrieved after institutional review board approval (no. 11-
001724).
Pancreas histology and stains. Tissue sections from rats and mice were
deparaffinized in toluene and rehydrated in an ethanol gradient. First, sections
were stained in Harris hematoxylin solution (HHS16; Sigma) and eosin Y so-
lution (HT110132; Sigma) to evaluate general histology. PDGs were defined
based on the previously described criteria (19) (Fig. 1). Sections were stained
by Alcian blue (Electron Microscopy Sciences) and p-aminosalicylic acid
(PAS) (Sigma).
For immunhistochemical-immunofluorescent staining, antigen retrieval was
performed via microwave heating in citrate buffer (H-3300; Vector, Burlingame,
CA), and slides were blocked in Tris-buffered saline (3% bovine serum albumin,
0.2% TX-100, and 2% bovine serum) for 1 h. The following primary antibodies
were used for the 12-h incubation (4°C): ductal cell marker cytokeratin (mouse
anti-pancytokeratin, 1:50 [Sigma] or rat anti-cytokeratin19/TROMAIII, 1:100
[Hybridoma Bank, University of Iowa, Iowa City, IA]); acinar cell marker
amylase (rabbit anti-amylase, 1:300; Abcam); proliferation marker anti–Ki-67
(1:50; Dako, Carpinteria, CA); GLP-1R (rabbit anti-human GLP-1R, NLS1206,
1:100; Novus Biologicals, Littleton, CO); and pancreatic and duodenal
homeobox-1 (Pdx-1) (rabbit anti–Pdx-1, 1:500; b-Cell Biology Consortium,
Nashville, TN). Validation of the GLP-1R antisera, NLS1206, was published
previously (22). Secondary antibodies labeled with Cy3 and fluorescein iso-
thiocyanate were obtained from The Jackson Laboratories (West Grove, PA)
and used at dilutions of 1:100 for the 1-h incubation at room temperature.
For immunohistochemical staining, endogenous peroxidase activity was
quenched with 10% methanol, 10% H202 in Tris-buffered saline, followed by
incubation with anti–Ki-67 (dilution 1:100; Dako) for 12 h (4°C). Subsequent
detection was performed with Envision+ anti-rabbit horseradish peroxidase
(Dako), with 39,39-diaminobenzidine used as the chromogen and hematoxylin
as the counterstain.
Likewise, sections of human pancreata were stained with hematoxylin and
eosin, Alcian blue, and PAS in order to permit the identification of PDGs and
PanIN lesions. Sections adjacent to those with PDGs and PanIN lesions also
were stained by immunofluorescence for cytokeratin and for GLP-1R (the same
antibodies and dilution as above).
Morphometric analysis of the pancreatic duct gland compartment in
rats. The slide with the greatest number of PDGs per animal was selected for
quantitative analysis. Slides were digitally scanned in the UCLA Translational
Pathology Core Laboratory using an Aperio ScanScope XT (Aperio Technol-
ogies, Vista, CA). Quantitative analysis was performed using Aperio Scanscope
software. The length of the large duct associated with PDGs and the mean
cross-sectional area per PDGweremeasured in each case. PDGs in the exendin-
4–treated rats often showed complex epithelial architecture, including cribiform
patterns and pseudopapillae, consistent with epithelial proliferation. The ducts
containing this complex PDG epithelial architecture appeared more dilated. To
quantify if ductal dilation was present, we measured the longest axis of the large
ducts present (duct length) and the inner circumference of the duct lumen. This
allowed us to compute a ratio (inner duct luminal circumference to duct length)
for each animal.
Histological analysis of chronic pancreatitis and murine PanIN (mPanIN)
lesions in Pdx1-Kras mice. Full histologic cross-sections of each pancreas
were stained with hematoxylin and eosin for histopathologic examination by two
subspecialty gastrointestinal pathologists (D.D. and S.M.D.) blinded to treatment
conditions. Chronic pancreatitis was graded using a semiquantitative scoring
system, as previously described (23), with slight modification. Chronic pan-
creatitis was given an index score (0–12) reflecting the sum of scores for
acinar loss, lobular inflammation, and fibrosis. Acinar loss was based on the
percentage loss across the entire cross-section and graded as 0, absent;
1, 1–25%; 2, 26–50%; 3, 51–75%; and 4, .75%. Inflammation was based on the
average number of lobular inflammatory cells per 403 high power field (HPF)
(as counted in 10 nonoverlapping HPFs) and graded as 0, absent; 1, 1–30 cells; 2,
31–50 cells; 3, 51–100 cells; and 4, .100 cells. Fibrosis was based on the cu-
mulative area of stromal fibrosis across the entire pancreas and graded as 0,
absent; 1, 1–5%; 2, 6–10%; 3, 11–20%; and 4, .20% fibrosis. Duct profiles were
evaluated according to established consensus guidelines for the histologic
evaluation of mPanIN (24) and quantified as previously described (25). All duct
profiles in one full pancreas cross-section were evaluated to determine the
relative proportions of nondysplastic (normal, reactive, and metaplastic) ducts
and each category of mPanIN lesion. The proportion of each mPanIN lesion to
the overall number of duct profiles was recorded for each animal.
Duct cell replication frequency. To determine the frequency of replication of
PDG cells and cells in the adjacent main ducts in the head of the pancreas in
rats, we quantified the percentage of Ki-67–positive cells. Thus, the total number
of duct cells (the head of the pancreas) evaluated was 57,261 in exendin-4–
treated rats and 61,298 in controls. We also evaluated the frequency of duct cell
replication in the sections of the tail of the pancreas immunostained for cyto-
keratin and Ki-67. The total number of duct cells evaluated from the tail was
24,483 in exendin-4–treated rats and 19,796 in controls.
Duct cell replication in pancreata from Pdx1-Kras mice also was analyzed by
Ki-67. The extensive acinar-to-ductal metaplasia and frequent dysplastic ductal
lesions in GLP-1–treated Pdx1-Kras mice precluded distinguishing replication
frequency in the various component of the ductal compartment (PDGs and
normal and dysplastic ducts). Slides were analyzed using the Ariol SL-50 au-
tomated slide scanner (Leica Microsystems) to quantitate the amount of
positive staining for each area of interest containing only ducts and dysplastic
ductal tissue. A total number of 121,883 (control group) and 101,830 (exendin-
4–treated group) cells were analyzed.
GLP-1 actions on pancreatic duct cells. In vitro experiments were carried
out to investigate the effects of exendin-4 on human pancreatic duct epithelial
(HPDE) cells (26,27). HPDE cells (kindly made available by Dr. Ming-Sound
Tsao, University of Toronto) were maintained in keratinocyte serum-free
media supplemented with bovine pituitary extract and human epidermal
growth factor (Invitrogen) at 37°C with 5% CO2. HPDE cells transfected with
the empty vector (pBabepuro) (HPDE-pBP) or with oncogenic pBP-Kras4BG12V
(HPDE-Kras) also were used to permit the assessment of GLP-1R activation in
the presence of an activating Kras mutation.
To assess the effect of exendin-4 (10 nmol/L) on the phosphorylation of
cAMP-responsive element-binding (CREB) protein and the mitogen-activated
protein kinases (MAPKs) extracellular signal–related kinase (ERK) 1/2, as well
as levels of the cyclin A and D1, 90,000 cells were seeded in six-well plates
containing complete medium. At ~70% confluence (day 3 after plating), cells
were rinsed with PBS and incubated in starvation medium (lacking bovine
pituitary extract and human epidermal growth factor) for 24 h. HPDE cells
containing either a control plasmid (pBabepuro; HPDE-pBP) or the mutated
oncogenic pBP-KrasG12V (28,29) were pretreated with 100 mmol/L metformin
for 30 min. For stimulation experiments, exendin-4 was added in fresh, pre-
warmed starvation medium for the indicated time points. Stimulation then was
stopped by adding ice-cold PBS, and HPDE cells were lysed in lysis buffer (50
mmol/L Hepes, 1% Nonidet P-40, 2 mmol/L Na3VO4, 100 mmol/L NaF, 10 mmol/L
PyrPO4, 4 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mg/mL
leupeptin, and 1 mg/mL aprotinin). Protein samples were denatured by boiling
at 95°C for 5 min, separated on 4–12% Bis-Tris NuPAGE gels (25–40 mg/lane;
Invitrogen), and blotted onto a polyvinylidene fluoride membrane (Fluoro-
Trans; Pall Life Sciences, Ann Arbor, MI). Membranes were probed with the
following primary antibodies (dilution for all 1:1,000): rabbit anti-CREB/
pCREB; rabbit anti-ERK1/2/pERK1/2 (both Cell Signaling); rabbit anti–cyclin A;
and rabbit anti–cyclin D1 (both Santa Cruz). After incubation with horseradish
peroxidase–conjugated secondary antibody (1:5,000; The Jackson Laborato-
ries), proteins were visualized using enhanced chemiluminescence (Millipore),
and levels were quantified using Labworks software (UVP, Upland, CA).
Analytical procedures. Plasma glucose concentrations were measured by the
glucose oxidase method (YSI Glucose Analyzer, Yellow Springs, OH). Plasma
lipase concentrations were measured by a colorimetric enzyme assay (BioAssay
Systems, Hayward, CA).
Statistical analysis. Statistical analysis was performed using the Student
t test or ANOVA, where appropriate (Statistica, version 6; Statsoft, Tulsa, OK).
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FIG. 1. The extent and frequency of PDGs surrounding the main pancreatic duct are increased by exendin-4 treatment in rats. Sections from the
head of the pancreas from an untreated control rat (A) and after 12 weeks of daily exendin-4 injections (E), in which PDG clusters were identified
surrounding the main pancreatic duct. PDGs were confined to the mesenchyme surrounding the main duct in controls but, after exendin-4, ex-
panded to the extent that they projected into the lumen of the pancreatic duct as complex villous-like structures. A and E, insets: PDG cells were
columnar in comparison with the cuboidal ductal cells and included goblet-like cells (arrowheads). B and C: PDGs contained mucin confirmed by
Alcian blue and PAS staining. D: In contrast to duct cells, PDG cells also expressed Pdx-1 (red; combined staining with the duct cell marker
cytokeratin [CK] in green). E: PDGs were more common in exendin-4–treated rats (Table 1). F–H: In addition, the epithelium often showed
pseudostratification and pseudopapillary features, which are features characteristic for PanIN-like lesions. Scale bars = 200 mm (A and E) and 100 mm
(B–D), and magnification 320 (F–H). (A high-quality digital representation of this figure is available in the online issue.)
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Data in graphs and tables are presented as means 6 SEM. Findings were
assumed statistically significant at P , 0.05.
RESULTS
Metabolic actions of exendin-4 in rats. Twelve weeks
of daily exendin-4 injections had the anticipated effects of
decreasing weight gain (66 6 8 vs. 164 6 5 g; P , 0.001
exendin-4 vs. control) and blood glucose levels (99 6 2 vs.
108 6 4 mg/dL; P , 0.01 exendin-4 vs. control). As
expected, exendin-4 decreased daily food intake (153 6 5
vs. 204 6 5 mg/day; P , 0.001 exendin-4 vs. control), but
the treated animals did not seem to be in any apparent pain
or distress (Supplementary Fig. 1).
Effects of exendin-4 on exocrine pancreas in rats.
Pancreas weight was comparable in the treated versus
control group (2.3 6 0.1 vs. 2.3 6 0.1 g; exendin-4 vs.
control). However, relative to body weight, pancreatic
weight in exendin-4–treated animals was increased (0.53 6
0.02 vs. 0.43 6 0.02; P , 0.01 exendin-4 vs. control)
(Supplementary Fig. 1D).
There was no histological evidence of pancreatitis in
either the exendin-4 or control group. Consistent with this,
lipase activity was not changed by exendin-4 (330 6 19 vs.
299 6 11 units/L; exendin-4 vs. control) (Supplementary
Fig. 1E). However, exendin-4 did induce a marked ex-
pansion of the PDG compartment (Fig. 1 and Supplemen-
tary Fig. 2). PDGs were identified, as previously described,
as blind outpouchings from large pancreatic ducts present
in the mesenchyme surrounding the ducts. PDG cells were
further distinguished from main duct cells by frequently
being columnar rather than cuboidal (Fig. 1A and E,
insets) and mucin positive (Alcian blue and PAS stains).
PDGs also expressed Pdx-1 (Figs. 1B–D). There was an
~70% increase in the number of PDGs per unit of length of
the main pancreatic duct following exendin-4 treatment
(526 7 vs. 316 4 PDGs/mm main duct; P, 0.05 exendin-4
vs. control) (Table 1). Moreover, the mean cross-sectional
area of individual PDGs still confined within the mesen-
chyme around the ducts was ~30% increased by exendin-4
treatment (1,1846 102 vs. 9106 45 mm2; P, 0.05 exendin-4
vs. control), a conservative estimate given that the expanded
PDGs adopt a more coiled structure as previously de-
scribed (19). The latter evaluation also likely underestimates
the extent of the expansion of PDGs in exendin-4–treated
rats because in many cases the PDGs also expanded into
the duct lumen with a complex cribriforming and papillary
architecture. To account for this, we quantified the extent
to which the main duct lumen was convoluted by any
intraluminal projection by computing the ratio of the cir-
cumference of the inner duct lumen to the duct length,
a metric that was ~35% increased in exendin-4–treated
animals (5.0 6 0.2 vs. 3.7 6 0.3; P , 0.01 exendin-4 vs.
control). With exendin-4, the epithelium also showed
variable nuclear pseudostratification and loss of polarity,
as well as micropapillary architecture (Fig. 1F–H), his-
tologic features that can be associated with PanIN lesions
and dysplasia when observed in human pancreas, although
the implications in rat pancreas are unknown. No car-
cinoma was seen. Collectively, these findings confirm an
increased number of PDGs and expansion of the epithelial
cell compartment of both PDGs and large ducts in re-
sponse to exendin-4 treatment.
The frequency of PDG cell replication was fourfold in-
creased in exendin-4 versus control rats (14.6 6 3.9 vs.
3.8 6 0.9%; P , 0.05 exendin-4 vs. control) (Fig. 2). The
frequency of replication in the main pancreatic ducts was
much lower than that in the PDGs but still increased
twofold by exendin-4 treatment (5.3 6 1.8 vs. 2.7 6 0.6%;
P , 0.05 exendin-4 vs. control). In contrast, there was no
statistically increased frequency of duct cell replication
with exendin-4 treatment in the small ducts of the tail of
the pancreas (0.62 6 0.17 vs. 0.42 6 13%; P = 0.4 exendin-4
vs. control).
Actions of GLP-1 mimetic treatment on the exocrine
pancreas in the Pdx1-Kras mutant mouse. In Pdx1-Kras
mice, 12 weeks of exendin-4 treatment had no impact on
body weight (23.2 6 1.2 vs. 25.8 6 1.7 g), food intake
(18.1 6 0.7 vs. 19.7 6 0.5 g per week), or blood glucose
levels (83.0 6 3.4 vs. 75.4 6 3.7 mg/dL) when compared
with littermate control mice. However, GLP-1 mimetic treat-
ment increased pancreatic weight (1.1 6 0.1 vs. 0.7 6 0.1 g;
exendin-4 vs. control) (Supplementary Fig. 3).
While overall lobular architecture was preserved in both
animal groups, the exendin-4–treated animals demon-
strated more extensive chronic pancreatitis with greater
loss of acini with replacement by reactive or metaplastic
duct profiles (Fig. 3). The percentage of pancreas com-
posed of acinar tissue was decreased by 61% by exendin-4
treatment (13.0 6 13.5% vs. 33.66 14.6%; P , 0.05 exendin-
4 vs. control). These changes were accompanied by in-
creased inflammation, more extensive stromal fibrosis, and
widespread reactive and metaplastic changes, as deter-
mined by pancreatitis score (10.0 6 1.2 vs. 8.6 6 0.8;
P , 0.05 exendin-4 vs. control). The plasma lipase activity
also was increased with exendin-4 (1,020 6 164 vs. 678 6
34 units/L; P , 0.05 exendin-4 vs. control) (Supplementary
Fig. 3). In comparison to control animals, treated animals
showed more extensive acinar-to-ductal metaplasia with
replacement of acini by ductules lined by mucin-producing
cells primarily with small, round basally oriented nuclei
without papillary features (mPanIN1). A minority of the duct
profiles demonstrated increased nuclear hyperchromasia
and pleomorphism with stratification and micropapillary
changes (mPanIN2 and mPanIN3) (Fig. 3). Moreover, GLP-1
mimetic treatment induced increased duct cell proliferation
(P , 0.05) in Pdx1-Kras mice when compared with control
animals (Fig. 4).
GLP-1R expression in PDGs and PanIN lesions. GLP-
1R expression was readily detected in pancreatic b-cells in
rat and human pancreas, serving as a positive control (data
not shown). GLP-1R expression also was present in PDG cells
in both rodent and in human pancreas (Fig. 5). GLP-1R ex-
pression was not detected in pancreatic acinar cells. GLP-1R
expression also was abundantly present in mPanIN lesions
TABLE 1
Analysis of the PDG compartment
Control Exendin-4
Number of PDGs/mm main duct 31 6 4 52 6 7*
PDG area (mm2) 910 6 45 1,184 6 102*
Main duct lining-to-length ratio 3.7 6 0.3 5.0 6 0.2†
To evaluate the extent of the PDG compartment in treated and con-
trol animals, we analyzed the PDG compartment in sections from the
head of the pancreas from 10 animals in each group (illustrated in
Supplementary Fig. 2). The number of PDGs per millimeter of main
duct (first row) and the average size of a PDG (second row) revealed
a marked expansion of the PDG compartment after exendin-4 treat-
ment. Furthermore, the main duct appears to be dilated because the
ratio of main duct lining to length was increased in the treated group
(third row). *P , 0.05. †P , 0.001.
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FIG. 2. PDG cell replication is increased by exendin-4 treatment in rats. The frequency of replication ascertained by Ki-67 immunostaining (red;
colabeled with cytokeratin [CK] in green) was increased in PDGs compared with adjacent duct cells (*lumen of the large duct) in both control (A)
and exendin-4–treated (B) rats. Replication frequency showed variation within the PDGs in control (C) as well as exendin-4–treated (D) animals.
E: However, both the abundance of PDGs and the frequency of replication were increased by exendin-4 treatment. Exendin-4 also increased
replication in main duct cells but not in the duct cells in the tail of the pancreas. □, control (Ctrl); ■, exendin-4 (Ex). *P < 0.05, scale bars = 100
mm. (A high-quality digital representation of this figure is available in the online issue.)
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FIG. 3. Exendin-4 treatment increased chronic pancreatitis and the frequency of mPanIN lesions in Pdx1-Kras mice. Pancreata from Pdx1-Kras
mice treated for 12 weeks with either vehicle (A) or exendin-4 (B) (203 objective). The pancreas from the exendin-4–treated animal demonstrates
only scant residual intact acini (white arrow) with more extensive inflammation and fibrosis (stars) and more frequent mPanIN (black arrows).
C and D: Low-grade mPanIN1a and mPanIN1b lesions with abundant apical mucin and basally oriented nuclei without significant nuclear pleo-
morphism or mitotic activity. E and F: Higher-grade mPanIN2 and mPanIN3 lesions with increased nuclear pleomorphism and focal loss of polarity.
G: Quantitative analysis of mPanINs showing the percentage of pancreatic ducts with no dysplasia (□, normal [nl]); light-grey box, mPanIN1 (1);
medium-grey box, mPanIN2 (2); or ■, mPanIN3 (3) lesions in control (Ctrl) and exendin-4 (Ex)-treated mice. H: Combined amylase (red) and
cytokeratin (CK; green) immunofluorescent staining of the pancreas of a control Pdx1-Kras mouse. I: Intact acinar tissue (red) is replaced by
cytokeratin-positive (green) ducts, and amylase-positive cells are rarely found in exendin-4–treated animals. Alcian blue staining (blue; coun-
terstained with Nuclear Fast red) reveals mucin-containing lesions in control mice (J) and a higher frequency in treated mice (K). *P< 0.05; **P<
0.01 vs. control. (A high-quality digital representation of this figure is available in the online issue.)
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FIG. 4. Duct cell replication frequency is increased in the pancreas of exendin-4–treated Pdx1-Kras mice. Immunohistochemical labeling of Ki-67–
positive cells (brown; counterstained with hematoxylin) in benign ducts in areas of intact acinar tissue in control mice (A) and exendin-4–treated
mice (B). An area of ductal proliferation embedded in fibrotic tissue shows an increase in Ki-67–positive cells in the exendin-4–treated group (D)
compared with controls (C). Note the presence of proliferative ducts and mPanIN1a lesion in the exendin-4–treated animal. E: Analysis of duct cell
proliferation by Ki-67 reveals an increase in the replication frequency in Pdx1-Kras mice treated with exendin-4 (Ex; ■) compared with vehicle
control (Ctrl; □). *P < 0.05. (A high-quality digital representation of this figure is available in the online issue.)
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in the pancreas of Pdx1-Kras mice and humans (Fig. 6).
GLP-1R was also detected in areas of acinar-to-ductal meta-
plasia as well as mPanIN lesions in Pdx1-Kras mice (Fig. 6A
and B). In humans, cells with a columnar phenotype had
prominent GLP-1R expression. For example, immunoreac-
tivity was present in PanIN1 lesions but only was minimally
detected in adjacent cells with normal cuboidal pancreatic
duct morphology in the same duct (Fig. 6C). In 6 of 10 hu-
man pancreata, GLP-1R expression was detected in a vari-
ety of ductal lesions (PanIN1a to PanIN3) (Fig. 6D and E).
Actions of exendin-4 treatment in human pancreatic
duct cells. GLP-1 activation of G-protein–coupled recep-
tors has been reported to activate multiple signaling path-
ways in pancreatic b-cells, such as the cAMP–protein kinase
A and the MAPK pathways leading to phosphorylation of
CREB with increased cyclin levels and b-cell replication in
pancreatic b-cells (30–32).
To investigate the mechanism of GLP-1–induced duct
cell proliferation, we treated HPDE cells with exendin-4
(Fig. 7). CREB phosphorylation increased after 10 min of
exendin-4 exposure, reaching a plateau at ~30 min (1.8 6
0.2-fold vs. control; P , 0.05; n = 3) (Fig. 7A). Exendin-4
induced a time-dependent phosphorylation of the mitogen-
activated kinases ERK1 (4.8 6 0.6-fold) and ERK2 (2.7 6
0.1-fold, respectively, vs. control at 10 min; P, 0.01; n = 3)
(Fig. 7B). Consequently, cyclin D1 protein was induced to a
maximum at ~6 h (1.56 0.2-fold vs. control; P, 0.05; n = 3)
(Fig. 7C). However, no changes were observed in cyclin
FIG. 5. GLP-1R expression is present in PDGs in rats and humans. A: In the PDGs (shown here for an exendin-4–treated rat), GLP-1R expression
(red) was detected by immunofluorescence with combined labeling for the duct cell marker cytokeratin (CK) in green and DAPI to mark the nuclei
in blue. B: Colocalization of GLP-1R and cytokeratin is indicated in the merged images by the color orange. GLP-1R expression was similarly
apparent in PDGs in duct cells in the human pancreas. Scale bars = 100 mm. (A high-quality digital representation of this figure is available in the
online issue.)
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FIG. 6. GLP-1R expression is present in PanIN lesions in Pdx1-Kras mice and humans. GLP-1R (red; shown with combined cytokeratin [CK] labeling
in green) was detected in areas of acinar-to-ductal metaplasia (ADM) (A) and mPanIN lesion (B) in the pancreas of Pdx1-Kras mice. Colocalization
of GLP-1R and cytokeratin is indicated in the merged images by the color orange. C: In human pancreas, GLP-1R expression was more apparent in
the columnar cells (arrowheads) in regular ducts compared with adjacent normal cuboidal duct cells shown away from the arrowhead. D: Where
duct cells adopt the columnar phenotype (PanIN1a lesion shown), GLP-1R expression becomes more apparent. E: In more advanced PanIN3 lesions,
GLP-1R immunoreactivity also was clearly present. Scale bars = 100 mm. (A high-quality digital representation of this figure is available in the
online issue.)
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A levels (Fig. 7D). We also investigated the actions of
exendin-4 with or without metformin in the presence of the
activating Kras mutation in HPDE cells. Exendin-4 induced
CREB phosphorylation in control (pBP) cells (1.4 6 0.1-
fold pCREB/CREB vs. control; P , 0.01; n = 3), an effect
that was more pronounced in the presence of mutant Kras
(1.7 6 0.1-fold vs. control; P, 0.001; n = 3), and this effect
was abrogated by metformin pretreatment (1.0 6 0.1-fold
vs. control; n = 3; P , 0.01 vs. exendin-4 treatment alone)
(Fig. 8).
DISCUSSION
The possibility that GLP-1 mimetic therapy might induce
sustained proliferative changes in the exocrine pancreas
is of concern because therapy for T2DM may be admin-
istered for decades (33,34). An increased reported ad-
verse event rate in the U.S. Food and Drug Administration
adverse-event reporting system for pancreatitis and pan-
creatic cancer in patients treated with GLP-1–based ther-
apy underscores this concern (35). Because T2DM with
obesity is a risk factor for pancreatitis and pancreatic
FIG. 7. Exendin-4 actions on human pancreatic duct cells. A and B: Time-course experiments of CREB (A) and ERK1/2 (B) phosphorylation in
HPDE cells treated with exendin-4 (10 nmol/L) for 0–30 min as indicated. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Representative
examples of Western blot experiments are shown in the top panels and the corresponding analysis in the bottom panels. C and D: Effect of long-
term (0–9 h) stimulation on cyclin D1 (C) and cyclin A (D) protein levels. Data are expressed as the mean6 SD density ratio of total CREB, ERK1/2
(A and B), as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (C and D) from 3 to 5 independent experiments. *P < 0.05; **P < 0.01;
***P < 0.001 vs. untreated control value.
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cancer (36,37), administration of a drug that may further
amplify those risks requires closer investigation. In con-
trast, also unexpectedly, the diabetes medication metformin
may decrease the risk of pancreatitis and pancreatic cancer
(38,39). Given the recent appreciation that PDGs can give
rise to PanIN-like lesions in the context of chronic pan-
creatitis (19), we first sought to establish the effects of GLP-
1R activation on this compartment.
Exendin-4 treatment for 12 weeks induced a marked
expansion of the PDG compartment in nondiabetic lean
Sprague-Dawley rats. If the pancreas had been sectioned
exclusively through the body or tail, no striking abnormal-
ities would have been observed, including no increase in the
frequency of replication of duct cells. The normal histology
in the most accessible portion of the pancreas and the ab-
sence of tumors or overt pancreatitis in lean nondiabetic
animals treated with exendin-4 may explain normal exo-
crine pancreas toxicology screens (40) and some animal
studies (17,18). Therefore, to observe the GLP-1–induced
changes in PDGs reported in rats here, methodical analysis
of the entire pancreas, to include longitudinal sections
through the main pancreatic duct, is necessary.
Because PDGs have properties of an adult stem cell
compartment (19), it is not surprising that short-term ac-
tivation of the PDGs by GLP-1 therapy coincident with
induced pancreatic injury facilitates recovery from that
injury, presumably by fostering regeneration and providing
increased protective mucin secretion (17,18). The clini-
cally more relevant question concerns the implication of
longer-term stimulation of the PDG compartment and its
derivatives.
A total of 12 weeks of exendin-4 therapy in young
healthy rats generated mucinous metaplasia and cytologic
atypia resembling low-grade PanIN-like lesions in the PDG
compartment, features reminiscent of the response to in-
duced chronic pancreatitis in mice and spontaneous
chronic pancreatitis in humans (19) (Fig. 1 and Supplementary
Fig. 2). However, we also report that GLP-1R expression
is present in PDGs and PanIN lesions in rodents and hu-
mans, raising the question, does GLP-1 mimetic therapy
stimulate the growth of PanIN lesions? Low-grade PanIN
lesions are present in 16–80% of normal adult pancreata,
the frequency increasing with age (41). PanIN lesions in
humans are considered neoplasms and potential precur-
sors for invasive pancreatic cancer based on both path-
ological findings in humans and longitudinal studies in
mice in which mutant Kras is introduced into the pancreas
(42). The activating point mutation in the KRAS gene is the
most frequent mutation present in human PanIN lesions and
is considered to be the first step in the progression toward
pancreatic cancer (42).
To better appreciate the actions of GLP-1–based therapy
in a progression model of PanIN to pancreatic cancer,
we treated Pdx1-Kras mice for 12 weeks with exendin-4.
Exendin-4 treatment increased duct cell replication, in-
creased the formation of dysplastic mPanIN lesions, and
accelerated the development of chronic pancreatitis. These
data are consistent with the hypothesis that PanIN lesions
contribute to the development of pancreatitis by the ob-
struction of ductal outflow, with the resulting chronic pan-
creatitis fostering further development of PanINs (42). The
dose of exendin-4 used here, although comparable with that
used previously to show the benefit in rodents, exceeds the
dose (per kilogram) used in humans (20). A lower dose was
used in a recent study to evaluate the effects of exendin-4
on the rodent exocrine pancreas in which no adverse
actions were reported (18). However, no data were pro-
vided in that report as to whether the dosage of exendin-4
achieved the clinically desired metabolic actions of exendin-
4. Moreover, the PDG compartment apparently was not
evaluated in those studies, and the animals were not pre-
disposed to dysplasia. It is unknown to date whether a dose
of GLP-1 mimetic therapy might be identified that has the
intended beneficial actions of enhanced glucose-mediated
insulin secretion but no proproliferative effects on the exo-
crine pancreas.
FIG. 8. Oncogenic Kras increases the effects of exendin-4 on human pancreatic duct cells, an effect that is counteracted by metformin. A: Rep-
resentative Western blot of extracts from HPDE cells stably transfected with control vector (pBP) or oncogenic Kras showing CREB phosphor-
ylation at Ser133. Cells were pretreated with metformin (Metf; 100 mmol/L) for 30 min as indicated, prior to a 15-min stimulation with exendin-4
(Ex; 10 nmol/L). Forskolin (Forsk; 10 mmol/L) was used as the positive control. B: Statistical analysis shows that phosphorylation of CREB by
exendin-4 is higher in HPDE-Kras when compared with HPDE-pBP cells (P < 0.05). Metformin treatment abrogated the effect of exendin-4 in
HPDE-Kras cells (P < 0.01) but not in HPDE-pBP cells. Data are expressed as the mean 6 SD density ratio of total CREB from five independent
experiments. *P < 0.05; **P < 0.01. Ctrl, control; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Evaluation of the proliferative actions of GLP-1 in the
exocrine pancreas in humans is not technically feasible.
Therefore, we examined the actions of exendin-4 on hu-
man pancreatic ductal epithelial cells in vitro. These in
vitro studies on the actions of GLP-1R activation in pan-
creatic duct cells revealed a proproliferative action me-
diated through the activation of MAPK pathways and
phosphorylation of CREB, which was even more apparent
in the setting of an activating Kras mutation and inhibited by
the actions of metformin. This provides a mechanistic basis
for the association of metformin treatment with decreased
risk for pancreatitis and pancreatic cancer in individuals
with T2DM (38,39). It is also consistent with a previous
rodent study in which metformin attenuated the pro-
liferative actions of the DPP-4 inhibitor sitagliptin on the
pancreatic ductal tree (3).
In conclusion, we report that treatment of rats for 12
weeks with exendin-4 induced a marked expansion of
PDGs through the mechanism of enhanced PDG cell rep-
lication. Moreover, we report that the PDGs in rats and
humans express GLP-1Rs and that these also are abun-
dantly expressed in PanIN lesions in human pancreas. GLP-1
treatment advances the rate of formation of dysplastic
mPanIN lesions and chronic pancreatitis in a mouse model
prone to the development of pancreatic ductal adenocarci-
noma. Finally, we report that treatment of human pancreatic
duct cells with the GLP-1 analog exendin-4 induces propro-
liferative signaling pathways, an effect that is inhibited by
metformin. Collectively, these studies imply that GLP-1–
induced proliferation within the exocrine pancreas is focal
and may accelerate the development of dysplastic lesions
when present.
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